Pharmaceutical Strategy White Paper
"The potential of in silico approaches to streamline drug development" This position paper highlights the potential of in silico medicine, using computational modelling and simulation to aid drug discovery, development, and delivery. It calls for adaptation of in silico technology to be a standard practice to complement in vivo and in vitro approaches in healthcare through a collaborative ecosystem of stakeholders.
Avicenna Alliance Days (AAD) 2023
DON'T LOOSE THE AVICENNA DAYS 2023 !!! We will give the entire healthcare community an exhaustive update on recent progress and achievements related to the adoption and deployment of in silico methods. We will review the plans to make digital evidences and in silico methods a reality in academic and industrial research, for both regulatory and clinical applications.
Avicenna Alliance Observer at IMDRF meeting in Brussels
The Avicenna Alliance had received the honor to be invited as an Observer to the International Medical Device Regulators Forum (IMDRF) meeting taking place in Brussels on March 27 & 28. An unique opportunity to learn, inform, network and share the central role of modeling and simulation (in silico methods) for regulatory approval.
Avicenna Alliance meets with MEPs in Strasbourg
During the European Parliament’s plenary session that took place in the second week of March, Avicenna had the unique opportunity to visit the European Parliament in Strasbourg, France to meet with policymakers and organise discussion about in silico medicine.
Welcome to our new member RBF Morph!
We are delighted to welcome our new member RBF Morph, a pioneer and leader in mesh morphing, a key technology used in engineering simulation.
Mimesis is a new Avicenna member!
We are truly delighted to welcome Mimesis as a new Avicenna member! Mimesis is an innovative start-up, founded in 2020 as a spinoff of the University of Catania, which offers to the biomedical industry and pharmaceutical companies the first generation of in Silico solutions.